Search results for: HTA
Filter search results
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and…
How is Quality of Life Measured for Health Technology Assessments?
1 July 2021
Cost-effectiveness analysis (CEA) is the economic evaluation method that is typically preferred by health technology assessment agencies. Quality-adjusted life years (QALYs) – a composite measure of quality and quantity of life – are often…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the National Institute of Health…
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
The National Institute for Health and Care Excellence (NICE) makes recommendations for the use of medicines in the National Health Service (NHS) in England based on their clinical and cost-effectiveness…
Paying for Cures
25 May 2020, 11:00pm
…for patients and industry alike? We will be exploring: What makes cures different in HTA? What is uniquely uncertain about cures? How can we understand the impact of this uncertainty…
Can we “Netflix” the Broken Antibiotics Market?
28 September 2022, 3:00pm
…evaluation of technologies and interventions to support the development of clinical, public health and social care guidance. His experience includes consideration of HTA issues arising from the availability of novel…
Chris Henshall
14 December 2016
…he was also Founding President of Health Technology Assessment international (HTAi). Chris is now drawing on this wealth of experience in his current role as an independent consultant on health,…
Register Now for the OHE Conference on Drug Development in 2022
2 July 2012
…and elsewhere, the EMA, HTA agencies, life sciences companies, and academia. Confirmed to date are: Dr Richard Barker, Director of the Centre for Accelerating Medical Innovations, University of Oxford Professor…
OHE has an Opening for an Economist
4 September 2012
…sector; familiarity with HTA and medicines pricing and reimbursement in practice in one or more countries; strong quantitative skills Applications must be received by Monday, 24 September 2012. Interviews for…